Knockdown of Protein Phosphatase 5 Inhibits Ovarian Cancer Growth

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Feb 13

PMID 26870184

Citations 8

Authors

Xiaojiao Zheng

Lianxiao Zhang

Bohong Jin

Fubin Zhang

Duoyi Zhang

Lining Cui

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the most common cause of gynecological cancer-related mortality. Serine/threonine protein phosphatase 5 (PP5, PPP5C) has been recognized to be involved in the regulation of multiple cellular signaling cascades that control diverse cellular processes, including cell growth, differentiation, proliferation, motility and apoptosis. In this study, to evaluate the functional role of PP5 in ovarian cancer cells, lentivirus-mediated RNA interference (RNAi) was applied to silence PPP5C in the human ovarian cancer cell line CAOV-3. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell colony forming ability was measured by colony formation. Cell cycle progression was determined by propidium iodide staining and flow cytometry. The results demonstrated that lentivirus-mediated RNAi specifically suppressed the expression of PPP5C at the mRNA and protein levels in CAOV-3 cells. Further investigations revealed that PP5 knockdown significantly inhibited the proliferation and colony formation of CAOV-3 cells. Moreover, the cell cycle of CAOV-3 cells was arrested at the G0/G1 phase following PP5 knockdown. This study highlights the crucial role of PP5 in promoting ovarian cancer cell proliferation, and provides a foundation for further study into the clinical potential of lentiviral-mediated delivery of PP5 RNAi therapy for the treatment of ovarian cancer.

Citing Articles

Closer to the Reality-Proteome Changes Evoked by Endometrial Scratching in Fertile Females.

Scheliga I, Baston-Buest D, Poschmann G, Stuehler K, Kruessel J, Bielfeld A Int J Mol Sci. 2023; 24(17).

PMID: 37686380 PMC: 10488085. DOI: 10.3390/ijms241713577.

MiR-520a-5p/PPP5C regulation pattern is identified as the key to gemcitabine resistance in pancreatic cancer.

Fu R, Shao Q, Yang B, Chen Y, Ye Q, Chen X Front Oncol. 2022; 12:903484.

PMID: 35957917 PMC: 9358958. DOI: 10.3389/fonc.2022.903484.

MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.

Bao F, Zhang L, Pei X, Lian C, Liu Y, Tan H PLoS One. 2021; 16(9):e0256995.

PMID: 34587164 PMC: 8480815. DOI: 10.1371/journal.pone.0256995.

MicroRNA-365b-3p represses the proliferation and promotes the apoptosis of non-small cell lung cancer cells by targeting PPP5C.

Zhang X, Wang J, Pan Y, Zhao J, Pan Y, Yan Y Oncol Lett. 2021; 21(5):389.

PMID: 33777212 PMC: 7988734. DOI: 10.3892/ol.2021.12650.

Structure and function of the co-chaperone protein phosphatase 5 in cancer.

Sager R, Dushukyan N, Woodford M, Mollapour M Cell Stress Chaperones. 2020; 25(3):383-394.

PMID: 32239474 PMC: 7193036. DOI: 10.1007/s12192-020-01091-3.

References

Zuo Z, Dean N, Honkanen R . Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest. J Biol Chem. 1998; 273(20):12250-8. DOI: 10.1074/jbc.273.20.12250. View

Urban G, Golden T, Aragon I, Cowsert L, Cooper S, Dean N . Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem. 2003; 278(11):9747-53. DOI: 10.1074/jbc.M210993200. View

Olsen J, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P . Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006; 127(3):635-48. DOI: 10.1016/j.cell.2006.09.026. View

Zhou G, Golden T, Aragon I, Honkanen R . Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J Biol Chem. 2004; 279(45):46595-605. DOI: 10.1074/jbc.M408320200. View

Yu Y, Zhang M, Zhang X, Cai Q, Hong S, Jiang W . Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells. J Hematol Oncol. 2014; 7:39. PMC: 4028110. DOI: 10.1186/1756-8722-7-39. View

Yang F, Stenoien D, Strittmatter E, Wang J, Ding L, Lipton M . Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res. 2006; 5(5):1252-60. DOI: 10.1021/pr060028v. View

Connarn J, Assimon V, Reed R, Tse E, Southworth D, Zuiderweg E . The molecular chaperone Hsp70 activates protein phosphatase 5 (PP5) by binding the tetratricopeptide repeat (TPR) domain. J Biol Chem. 2013; 289(5):2908-17. PMC: 3908423. DOI: 10.1074/jbc.M113.519421. View

Yamaguchi F, Umeda Y, Shimamoto S, Tsuchiya M, Tokumitsu H, Tokuda M . S100 proteins modulate protein phosphatase 5 function: a link between CA2+ signal transduction and protein dephosphorylation. J Biol Chem. 2012; 287(17):13787-98. PMC: 3340197. DOI: 10.1074/jbc.M111.329771. View

Hoffert J, Pisitkun T, Wang G, Shen R, Knepper M . Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci U S A. 2006; 103(18):7159-64. PMC: 1459033. DOI: 10.1073/pnas.0600895103. View

10.

Chinkers M . Targeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor. Proc Natl Acad Sci U S A. 1994; 91(23):11075-9. PMC: 45169. DOI: 10.1073/pnas.91.23.11075. View

11.

Wechsler T, Chen B, Harper R, Morotomi-Yano K, Huang B, Meek K . DNA-PKcs function regulated specifically by protein phosphatase 5. Proc Natl Acad Sci U S A. 2004; 101(5):1247-52. PMC: 337038. DOI: 10.1073/pnas.0307765100. View

12.

Zuo Z, Urban G, Scammell J, Dean N, McLean T, Aragon I . Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry. 1999; 38(28):8849-57. DOI: 10.1021/bi990842e. View

13.

Ham B, Jayachandran H, Yang F, Jaitly N, Polpitiya A, Monroe M . Novel Ser/Thr protein phosphatase 5 (PP5) regulated targets during DNA damage identified by proteomics analysis. J Proteome Res. 2009; 9(2):945-53. PMC: 2818885. DOI: 10.1021/pr9008207. View

14.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

15.

Ballif B, Roux P, Gerber S, MacKeigan J, Blenis J, Gygi S . Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A. 2005; 102(3):667-72. PMC: 545566. DOI: 10.1073/pnas.0409143102. View

16.

Chinkers M . Protein phosphatase 5 in signal transduction. Trends Endocrinol Metab. 2001; 12(1):28-32. DOI: 10.1016/s1043-2760(00)00335-0. View

17.

Chalmers M, Kolch W, Emmett M, Marshall A, Mischak H . Identification and analysis of phosphopeptides. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 803(1):111-20. DOI: 10.1016/j.jchromb.2003.09.006. View

18.

Silverstein A, Galigniana M, Chen M, Chinkers M, Pratt W . Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem. 1997; 272(26):16224-30. DOI: 10.1074/jbc.272.26.16224. View

19.

Huang S, Shu L, Easton J, Harwood F, Germain G, Ichijo H . Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem. 2004; 279(35):36490-6. DOI: 10.1074/jbc.M401208200. View

20.

von Kriegsheim A, Pitt A, Grindlay G, Kolch W, Dhillon A . Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol. 2006; 8(9):1011-6. DOI: 10.1038/ncb1465. View